Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 12;15(12):1542.
doi: 10.3390/ph15121542.

Hepatitis B Therapeutic Vaccine: A Patent Review

Shuaibu Abdullahi Hudu  1 , Abdulgafar Olayiwola Jimoh  2 , Kasimu Ghandi Ibrahim  1 , Ahmed Subeh Alshrari  3
Affiliations

Hepatitis B Therapeutic Vaccine: A Patent Review

Shuaibu Abdullahi Hudu et al. Pharmaceuticals (Basel). .

Abstract

Viral hepatitis has long been underrated as a danger to global health. The UN only recently called for worldwide action to tackle viral hepatitis and lessen the disease burden in its "2030 Agenda for Sustainable Development". Hepatitis B virus (HBV), which causes liver cirrhosis and malignancy, is a main cause of death globally. This review analyses innovative HBV therapeutic vaccine candidates for which a patent was filed between January 2010 and March 2022 and presents future improvement techniques for vaccine efficacy. Although there is a preventative vaccine for HBV infection, over 3% of people worldwide have the disease on a long-term basis and can no longer benefit from it. Most people will have chronic HBV infection for the rest of their lives once it has been diagnosed. Moreover, only a small percentage of treated patients experience a functional cure with persistent hepatitis B surface antigen reduction. A significant proportion of deaths are caused by liver cirrhosis and hepatocellular cancer, which are both caused by chronic hepatitis B infection. Hence, there is an urgent need for novel medications due to the inadequacies of the current therapies.

Keywords: clinical trial; hepatitis B infection; patent review; therapeutic; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors have no affiliations or relevant financial relationships to any business or organization that would have a financial interest in or a conflict of interest with the information in the paper. Included in this are wages, honoraria, stock ownership, options, consultancy fees, royalties, grants or patents that have been received or are pending, as well as expert testimony.

References

    1. Ho J.K.-T., Jeevan-Raj B., Netter H.-J. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses. 2020;12:126. doi: 10.3390/v12020126. - DOI - PMC - PubMed
    1. Kidd-Ljunggren K., Miyakawa Y., Kidd A.H. Genetic variability in hepatitis B viruses. J. Gen. Virol. 2002;83:1267–1280. doi: 10.1099/0022-1317-83-6-1267. - DOI - PubMed
    1. Sunbul M. Hepatitis B virus genotypes: Global distribution and clinical importance. World J. Gastroenterol. 2014;20:5427, 5434. doi: 10.3748/wjg.v20.i18.5427. - DOI - PMC - PubMed
    1. Liu Z., Zhang Y., Xu M., Li X., Zhang Z. Distribution of hepatitis B virus genotypes and subgenotypes: A meta-analysis. Medicine. 2021;100:e27941. doi: 10.1097/MD.0000000000027941. - DOI - PMC - PubMed
    1. Tatematsu K., Tanaka Y., Kurbanov F., Sugauchi F., Mano S., Maeshiro T., Nakayoshi T., Wakuta M., Miyakawa Y., Mizokami M. A Genetic Variant of Hepatitis B Virus Divergent from Known Human and Ape Genotypes Isolated from a Japanese Patient and Provisionally Assigned to New Genotype J. J. Virol. 2009;83:10538–10547. doi: 10.1128/JVI.00462-09. - DOI - PMC - PubMed

LinkOut - more resources